The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

After his brother's diagnosis, columnist Sam Kirton has new questions about the nature of familial idiopathic pulmonary fibrosis.

Leerink Partners analyst Faisal Khurshid has maintained their bullish stance on PLRX stock, giving a Buy rating on September 13. Faisal ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

For this study, researchers used Pirfenidone, which is commonly used to treat idiopathic pulmonary fibrosis. But other ...